CYTK Cytokinetics, Incorporated

NASDAQ
$74.13

Cytokinetics, Incorporated (CYTK) is expected to report earnings on November 5, 2026, after the market close. The consensus earnings estimate is a loss of $1.54 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -8.7% since its last earnings release on August 6, 2026.

Cytokinetics, Beat Consensus Estimates
Thursday, August 6, 2026 · 4:00 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 5
Thursday · 4:05 PM ET
Earnings Whisper
-
vs ($1.54)
Rev est $30.27M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $75.85

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Cytokinetics, Incorporated

Cytokinetics Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.

Sector

Healthcare

Industry

Biotechnology